Kimberly-Clark is reshaping itself around a larger consumer-health and personal-care portfolio after selling a 51% stake in its International Family Care and Professional business to help fund Kenvue. The Kenvue merger has already been approved by both shareholder bases and remains targeted for the fourth quarter of 2026, subject to regulatory and other closing conditions.
The filing makes the deal’s economic footprint concrete, rather than changing the deal itself. Preliminary purchase consideration is $34.7 billion, consisting of $6.7 billion in cash and roughly $28.0 billion of K-C stock and replacement awards. The transaction is therefore mostly known, but this filing supplies the first consolidated view of what the combined balance sheet and earnings profile could look like.
| Pro forma metric | Six months ended June 30, 2026 | Year ended December 31, 2025 |
|---|---|---|
| Net sales | $16.17B | $31.48B |
| Operating profit | $2.75B | $3.52B |
| Net income attributable to K-C | $1.75B | $2.11B |
| Diluted EPS | $2.83 | $3.43 |
| Long-term debt | $18.22B | — |
| Diluted shares outstanding | 616.3M | 615.6M |
Scale improves, but the financing burden is substantial. The pro forma company combines K-C’s continuing operations with Kenvue’s roughly $15.3 billion of 2025 sales, while assuming $4.9 billion of new permanent debt financing. Pro forma long-term debt reaches $18.2 billion, versus K-C’s standalone $6.5 billion before the transaction, and annualized interest expense rises by $255 million in the 2025 illustration. That makes the deal dependent on operating execution, not just the strategic logic of combining brands.
Shareholder dilution is also a central cost of the transaction. K-C expects to issue 280.9 million shares to Kenvue holders, lifting the pro forma diluted share count to 616.3 million from K-C’s historical 333.3 million. 〔0〕 The filing’s pro forma diluted EPS of $2.83 is not a forecast or a synergy-adjusted target; it is an accounting illustration that reflects the larger share count, new interest expense, and purchase-accounting charges.
The filing leaves the potential upside outside the numbers. K-C says the pro forma statements do not include anticipated synergies, operating efficiencies, or cost savings. 〔1〕 At the same time, the purchase accounting creates $31.4 billion of identifiable intangible assets and $13.3 billion of estimated goodwill, producing $119 million of incremental amortization in the first six months of 2026 and $240 million for 2025.
The numbers remain preliminary, so the final economics can still move. K-C has not completed the valuation of all Kenvue assets and liabilities, and the purchase consideration will fluctuate with K-C’s share price until closing. The filing therefore clarifies the transaction’s scale and funding mechanics, but does not yet establish the final post-close earnings profile.
Bottom line: This is a major clarification of a well-known acquisition, not a new strategic surprise. Kenvue adds meaningful scale, but the filing makes clear that Kimberly-Clark is paying for it with heavy debt, substantial share issuance, and execution-dependent synergies.
Read the original 8-K on SEC EDGAR ↗